GEN Exclusives

More »

GEN News Highlights

More »
Oct 9, 2009

FDA Notifies Spectrum that Its sNDA Does Not Support Fusilev Approval in Colorectal Cancer

  • FDA has issued Spectrum Pharmaceuticals a complete response letter stating that the sNDA for Fusilev did not demonstrate that it was “noninferior” to leucovorin in treating advanced metastatic colorectal cancer. The company will request a meeting with the agency to discuss options for Fusilev in this indication.

    Spectrum’s drug, a novel folate analog, is already sanctioned for use after high-dose methotrexate therapy in osteosarcoma. It is also approved to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. It is available in vials as freeze-dried powder. The firm’s sNDA covered Fusilev for injection as a treatment for patients with advanced metastatic colorectal cancer.

    Leucovorin, a folic acid analog, is also approved to prevent harmful effects of methotrexate when used in certain cancers and to treat people who have accidentally received an overdose of methotrexate or similar medications.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »